STOP Fentanyl Act of 2021
- Last Action
- 10/19/2021
Actions
- 2021-10-19Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
- 2021-04-13Referred to the Subcommittee on Health.
- 2021-04-05Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2021-04-05Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2021-04-05Introduced in House
- 2021-04-05Introduced in House
CRS Summary
As of 2021-04-05 (00)
Support, Treatment, and Overdose Prevention of Fentanyl Act of 2021 or the STOP Fentanyl Act of 2021
This bill addresses data collection, treatment, harm reduction, and other issues related to substance misuse and addiction. It particularly focuses on opioids, fentanyl, and related substances.
Specifically, the bill expands surveillance of fentanyl and related substances. This includes establishing a pilot program to screen for contaminants in illicit drugs and a grant program to collect data on fentanyl-involved overdoses. The bill also specifies requirements concerning the collection and use of information about drugs seized by law enforcement.
Additionally, the bill establishes and modifies requirements to increase access to treatment and prevention services. For example, the Bureau of Prisons must make certain services, including medication-assisted treatments, available to individuals in its custody. The bill also
- repeals a provision that requires dependence on opioids for at least one year before an individual may be admitted to certain treatment programs;
- allows providers to prescribe medications to treat substance use disorders following a telehealth evaluation;
- creates grant programs for treatment and harm reduction activities; and
- addresses issues pertaining to opioid overdose reversal drugs.
Furthermore, the bill limits civil and criminal liability under specified laws for individuals who administer opioid overdose reversal drugs to an individual who reasonably appears to be experiencing an overdose, as well as for individuals who seek medical attention for themselves or on behalf of another for a drug overdose.
The bill also requires multiple reports, including a report by the Department of State on foreign sources of certain drugs.
Cosponsors (13)
- Lisa Blunt Rochester (D-DE)
- Theodore Deutch (D-FL)
- David Trone (D-MD)
- TIM RYAN (D-OH)
- Paul Tonko (D-NY)
- Madeleine Dean (D-PA)
- Don Bacon (R-NE)
- Joseph Morelle (D-NY)
- Peter Welch (D-VT)
- Debbie Dingell (D-MI)
- Jimmy Panetta (D-CA)
- Dean Phillips (D-MN)
- Teresa Leger Fernandez (D-NM)
Subjects
- American Samoa
- Cardiovascular and respiratory health
- Civil actions and liability
- Congressional oversight
- Corporate finance and management
- Correctional facilities and imprisonment
- Criminal investigation, prosecution, interrogation
- Criminal justice information and records
- Criminal procedure and sentencing
- Customs enforcement
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Drug trafficking and controlled substances
- Drug, alcohol, tobacco use
- Emergency medical services and trauma care
- Federal preemption
- Government information and archives
- Government studies and investigations
- HIV/AIDS
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.